Shanghai Pharmaceutical (601607.SH) announced that recently, folic acid tablets (5mg) from Changzhou Pharmaceutical Factory, a subsidiary of the company, received a notice of approval for Drug Supplement issued by the State Drug Administration, which was the first in China to pass the consistency evaluation of the quality and efficacy of generic drugs.

Folic acid belongs to B vitamins. Folic acid is a kind of vitamins that maintain cell function, metabolism and growth. Folic acid plays an important role in nucleic acid and protein synthesis, amino acid transformation, purine synthesis and DNA synthesis and metabolism. Many enzyme reactions in the body play a coenzyme role. It is mainly used for folic acid deficiency caused by various causes and megaloblastic anemia caused by folic acid deficiency and folic acid deficiency caused by chronic hemolytic anemia. it can prevent fetal neural tube defects for women who plan to become pregnant and are known to be at risk.

The drug was developed by WYETH PHARMS INC (Wyeth) and was first marketed in the United States in 1947. In September 2019, Changzhou Pharmaceutical Factory applied to the State Drug Administration for the evaluation of the consistency of the generic drug and was accepted. As of the date of this announcement, the company has invested about 5.8935 million yuan in R & D cost for the consistency evaluation of the drug.

As of the date of this announcement, the main manufacturers of the drug in China are North China Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., Jiangsu Lianhuan Pharmaceutical Co., Ltd.

According to the IQVIA database, the purchase amount of the drug hospital in 2021 is 187.41 million yuan. In 2021, the sales income of Changzhou Pharmaceutical Factory was 102.32 million yuan.